ARS Pharmaceuticals, Inc. (SPRY) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to ARS Pharmaceuticals' first quarter 2026 earnings conference call. At this time, all participants are in a listen-only mode. After the company's prepared remarks, we'll open the line for questions. Please be advised that today's conference is being recorded. I will now turn the call over to Justin Chokmah, Chief Business Officer. Please go ahead. Good morning and thank you for joining our first quarter 2026 earnings conference call. With me on the call are Richard Lowenthal, our co-founder, president, and CEO, Eric Karras, our Chief Commercial Officer, and Kathy Scott, our Chief Financial Officer. Earlier this morning, we issued a press release detailing our financial results and commercial highlights for the first quarter of 2026. That press release and our slide presentation are available in the Investors and Media section of our website. Before we begin, please note that today's remarks may contain forward-looking statements. Actual results may differ materially. please refer to our press release and SEC filings for further risk disclosures. With that, I'll turn the call over to Rich. Thank you, Justin, and good morning, everybody, and thank you for joining us on the call. We are off to a strong start in 2026, following our first full year as a commercial company and building momentum across the business. During the quarter, we continue to focus on key drivers of growth, which are expanding access, making NEFI more affordable to patients and caregivers, increasing prescriber adoption, and strengthening consumer awareness. We have made progress in further positioning NEFI as a differentiated and increasingly scalable treatment within a large market of type 1 allergic reactions, including anaphylaxis. In the first quarter, we generated $22...